Not All HAs are Created Equal

DUROLANE’s key advantages matter for your knee OA patients

DUROLANE, a single-injection hyaluronic acid (HA) treatment, can significantly improve the quality of life for knee osteoarthritis (OA) patients as soon as 2 weeks after injection.20


Prescribing Information


DUROLANE has the highest reported molecular weight of any HA—1015kDa.‡43,46

Here are more of DUROLANE’s key advantages:

DUROLANE is a non-animal, stabilized HA that is cross-linked and entangled to create an HA with a long residence time.10

Get in touch with a Rep



  • A half-life of 30 days (approximately 4 weeks) in the knee joint in a single-injection treatment regimen35
  • The longest reported half-life of any HA32-35


DUROLANE is the only FDA-approved single-injection HA for the treatment of knee OA pain proven to be clinically equivalent to a five-injection therapy.13,24

In a Level 1 study:11

  • DUROLANE was proven to be non-inferior to a steroid at 6 weeks.||
  • Researchers found a significant reduction in WOMAC pain from baseline with DUROLANE vs a steroid at week 26 [p=0.034]

See more science driven results

Find a sales representative or contact us with your questions about DUROLANE

    I am a:


    ‡Based on theoretical calculations
    §Animal performance may not be predictive of performance in humans.
    ||Methylprednisolone acetate (MPA)
    ¶The primary outcome was the WOMAC pain responder rate, defined as at least 40% relative improvement and 5-point absolute improvement from baseline values at 12 weeks.